Himalaya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 3.56 Cr
as on 17-12-2024
- Company Age 12 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.25 Cr
as on 17-12-2024
- Revenue -84.65%
(FY 2020)
- Profit 22.03%
(FY 2020)
- Ebitda -104.34%
(FY 2020)
- Net Worth -7.70%
(FY 2020)
- Total Assets -2.67%
(FY 2020)
About Himalaya Pharmaceuticals
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 3.56 Cr.
The company has closed loans amounting to ₹6.25 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Manoj Kumar, Rajinder Kumar, and Sunil Garg serve as directors at the Company.
- CIN/LLPIN
U24232PB2012PLC036630
- Company No.
036630
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
07 Sep 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Mansa, Punjab, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Himalaya Pharmaceuticals Limited offer?
Himalaya Pharmaceuticals Limited offers a wide range of products and services, including Chemical Reagents & Catalysts, Inorganic Salts.
Who are the key members and board of directors at Himalaya Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Kumar  | Director | 07-Sep-2012 | Current |
| Rajinder Kumar | Director | 07-Sep-2012 | Current |
| Sunil Garg | Director | 07-Sep-2012 | Current |
Financial Performance of Himalaya Pharmaceuticals.
Himalaya Pharmaceuticals Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 84.65% decrease. The company also saw a substantial improvement in profitability, with a 22.03% increase in profit. The company's net worth dipped by a decrease of 7.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Himalaya Pharmaceuticals?
In 2018, Himalaya Pharmaceuticals had a promoter holding of 60.97% and a public holding of 39.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Orintal Bank Of Commerce Creation Date: 19 Jun 2015 | ₹6.25 Cr | Satisfied |
How Many Employees Work at Himalaya Pharmaceuticals?
Unlock and access historical data on people associated with Himalaya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Himalaya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Himalaya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
